RADIOTHERAPY
JUST Leveled Up



Watch video

 

Turning cancer on
itself > Finally

SCINTIX® biology-guided radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.

SELF-DRIVING RADIOTHERAPY

When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our X1 platform uses to manage motion and treat solid tumors of any stage disease.

Targeting Cancer

Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.

ANY STAGE TUMOR

Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.

Combination Treatment

Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.

Learn more about our breakthrough technology

SCINTIX Biology-guided Radiotherapy

By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.

Clinicians

Discover SCINTIX therapy.

Cancer Centers

See how SCINTIX therapy can play a role
in your cancer program.

Make every day count

See Available Positions

Latest

Press Releases

RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center

HAYWARD, Calif., Feb. 10, 2025 – RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1. “At BHCC, we are committed to advancing cancer care by integrating the […]

View All Press chevron right

Blog

SCINTIX Therapy Leverages Breakthrough Device Status to Garner Accretive New Technology Reimbursement

In a landscape of declining Medicare reimbursements for conventional radiotherapy over the past decade, SCINTIX® therapy stands alone as a new modality in radiation therapy that bucks the trend. In January 2024, SCINTIX therapy was granted accretive reimbursement compared to other radiotherapy modalities. The Centers for Medicare and Medicaid Services (CMS) established a national payment […]

View All Blog Posts chevron right

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up